相关实验视频

Updated: May 24, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

在侵袭性乳腺癌中,Cyclin D1和Claudin-1的表达及其与临床病理学参数的相关性

Roopali Sehrawat¹, Vishesh Dhawan², Maitrayee Roy²

¹Department of Pathology, SGT Medical College Hospital and Research Institute, SGT University, Gurugram, Haryana, India.

Iranian journal of pathology

|March 4, 2025

概括

环素D1和克劳丁-1是乳腺癌预后的有希望的免疫组织化学 (IHC) 标记物. 环素D1与更好的结果相关,而克劳丁-1可能表明三阴性瘤,提供具有成本效益的替代品.

科学领域:

在瘤学瘤学.
病理学病理学病理学
生物标志物研究生物标志物研究

背景情况:

乳腺癌在临床结果中表现出显著的异质性,尽管具有相似的风险因素和治疗方法.
传统的预后标志物包括雌激素受体 (ER),孕激素受体 (PR) 和HER2/neu.
在乳腺癌管理中需要具有成本效益和可访问的预后工具.

研究的目的:

评估cyclin D1和claudin-1作为替代免疫组织化学 (IHC) 标记物用于乳腺癌预后的实用性.
评估环林D1和Claudin-1表达与侵袭性乳腺癌的临床病理特征的相关性.

主要方法:

对50例侵袭性乳腺癌病例进行了回顾性研究.
免疫组织化学 (IHC) 用于评估ER,PR,HER2/neu,Claudin-1和Cyclin D1.1的表达.
在标记物表达和临床病理学参数之间进行了相关性分析.

主要成果:

环素D1表达与节点状况参与 (P=0.011) 和光线型乳腺癌 (P=0.023) 呈现出统计学上显著的相关性.
克劳丁-1表达与临床病理特征没有显著的相关性,但在光线和HER2/neu阳性瘤中呈阳性.
循环D1阳性与更好的预后指标有关.

结论:

环素D1和克劳丁-1是乳腺癌的有价值的IHC标记物.
环素D1的表达可能表明预后有利.
克劳丁-1阴性可能与三阴性乳腺癌有关,这表明IHC是资源有限的环境中分子技术的经济有效替代品.

关键词:

乳腺癌乳腺癌乳腺癌克劳丁-1 是一种蛋白质.环 D1 环 D1 是一种免疫组织化学免疫组织化学

更多相关视频

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...